44 related articles for article (PubMed ID: 20818716)
1. Plasma filtration in the treatment of Graves' ophthalmopathy: A randomized study.
Cap J; Ceeova V; Skacha M; Rezek P; Vlcek P; Blaha M
J Clin Apher; 2010; 25(4):209-15. PubMed ID: 20818716
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
3. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
4. A pilot study to monitor Graves' ophthalmopathy with a combination of pattern-reversal and motion-onset visual evoked potentials.
Szanyi J; Kremlacek J; Kubova Z; Langrova J; Kuba M
J Clin Apher; 2012; 27(6):295-301. PubMed ID: 22811284
[TBL] [Abstract][Full Text] [Related]
5. Management of Graves' ophthalmopathy.
Wiersinga WM
Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):396-404. PubMed ID: 17452966
[TBL] [Abstract][Full Text] [Related]
6. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial.
Wakelkamp IM; Baldeschi L; Saeed P; Mourits MP; Prummel MF; Wiersinga WM
Clin Endocrinol (Oxf); 2005 Sep; 63(3):323-8. PubMed ID: 16117821
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of thyroid-associated ophthalmopathy: comparative study between prednisone and COP therapy].
Min HY; Liu XP; Jiang RX; Lian L; Hu TS
Zhonghua Yan Ke Za Zhi; 2005 Sep; 41(9):781-5. PubMed ID: 16191342
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging determination of extraocular eye muscle volume in patients with thyroid-associated ophthalmopathy and proptosis.
Kvetny J; Puhakka KB; Røhl L
Acta Ophthalmol Scand; 2006 Jun; 84(3):419-23. PubMed ID: 16704711
[TBL] [Abstract][Full Text] [Related]
10. The application of temperature measurement of the eyes by digital infrared thermal imaging as a prognostic factor of methylprednisolone pulse therapy for Graves' ophthalmopathy.
Shih SR; Li HY; Hsiao YL; Chang TC
Acta Ophthalmol; 2010 Aug; 88(5):e154-9. PubMed ID: 20553230
[TBL] [Abstract][Full Text] [Related]
11. A treatment strategy for Graves' orbitopathy.
Marcocci C; Pinchera A; Marinò M
Nat Clin Pract Endocrinol Metab; 2007 May; 3(5):430-6. PubMed ID: 17452970
[TBL] [Abstract][Full Text] [Related]
12. Peripheral parameters of oxidative stress in patients with infiltrative Graves' ophthalmopathy treated with corticosteroids.
Bednarek J; Wysocki H; Sowiński J
Immunol Lett; 2004 May; 93(2-3):227-32. PubMed ID: 15158621
[TBL] [Abstract][Full Text] [Related]
13. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
Wakelkamp IM; Prummel MF; Wiersinga WM
Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
[TBL] [Abstract][Full Text] [Related]
14. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy.
Prummel MF; Wiersinga WM; Mourits MP; Koornneef L; Berghout A; van der Gaag R
Arch Intern Med; 1990 May; 150(5):1098-101. PubMed ID: 1691908
[TBL] [Abstract][Full Text] [Related]
15. Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves' disease differ and suggest ophthalmopathy is a multiantigenic disease.
Goh SY; Ho SC; Seah LL; Fong KS; Khoo DH
Clin Endocrinol (Oxf); 2004 May; 60(5):600-7. PubMed ID: 15104563
[TBL] [Abstract][Full Text] [Related]
16. The relationship between anti-human eye muscle antibodies and thyroid function, anti-TSH receptor antibodies and eye symptoms in Graves' ophthalmopathy.
Molnár I; Balázs C
Wien Klin Wochenschr; 1992; 104(24):744-7. PubMed ID: 1363165
[TBL] [Abstract][Full Text] [Related]
17. [Corticosteroids and radiotherapy in the treatment of Graves' ophthalmopathy].
Nasr E; Khater S; Nehme-Nasr D; Azoury F; Jambart S
J Med Liban; 2010; 58(2):86-90. PubMed ID: 20549894
[TBL] [Abstract][Full Text] [Related]
18. Thyrotropin receptor antibodies detected by the human recombinant TBII assay--a surrogate marker for autoimmune activity in Graves' ophthalmopathy?
Myśliwiec J; Kretowski A; Stepień A; Mirończuk K; Kinalska I
Med Sci Monit; 2002 Sep; 8(9):MT159-62. PubMed ID: 12218953
[TBL] [Abstract][Full Text] [Related]
19. The effect of etanercept on Graves' ophthalmopathy: a pilot study.
Paridaens D; van den Bosch WA; van der Loos TL; Krenning EP; van Hagen PM
Eye (Lond); 2005 Dec; 19(12):1286-9. PubMed ID: 15550932
[TBL] [Abstract][Full Text] [Related]
20. Methylprednisolone increases plasma leptin levels in Graves' hyperthyroidism patients with active Graves' ophthalmopathy.
Song YM; Lee WJ; Chen MD; Kao CH; Sheu WH
Horm Metab Res; 2000 Jul; 32(7):277-82. PubMed ID: 10965934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
